secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001104659-26-029912
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses
--------------------------------------------------------------------------------

- Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.
- Part 3A tests one-step titration to 48 mg; Part 3B two-step to 64 mg; primary endpoints safety/tolerability.
- Initial dosing expected April 2026; data readout expected Q4 2026.
- CEO cites prior 48 mg cohort results: ~9% weight loss, improved glycemic control, favorable safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/0001104659-26-029912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926029912/mtva-20260318x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-029912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer